Antiviral drug

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Antiviral drugs are a class of medication used for treating viral infections.[1] Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses.[2] Unlike most antibiotics, antiviral drugs do not destroy their target pathogen; instead they inhibit its development.

Antiviral drugs are one class of antimicrobials, a larger group which also includes antibiotic (also termed antibacterial), antifungal and antiparasitic drugs,[3] or antiviral drugs based on monoclonal antibodies.[4] Most antivirals are considered relatively to the host, and therefore can be used to treat infections. They should be distinguished from viricides, which are not medication but deactivate or destroy virus particles, either inside or outside the body. Natural viricides are produced by some plants such as eucalyptus and Australian tea trees.[5]

Medical uses[edit]

Most of the antiviral drugs now available are designed to help deal with HIV, herpes viruses, SARS-CoV-2, the hepatitis B and C viruses, and influenza A and B viruses.[citation needed] Researchers are working to extend the range of antivirals to other families of pathogens.


The emergence of antivirals is the product of a greatly expanded knowledge of the genetic and molecular function of organisms, allowing biomedical researchers to understand the structure and function of viruses, major advances in the techniques for finding new drugs, and the pressure placed on the medical profession to deal with the human immunodeficiency virus (HIV), the cause of acquired immunodeficiency syndrome (AIDS).



Antiviral drug design[edit]

Anti-viral targeting[edit]




Approaches by virus life cycle stage[edit]


Researchers working on such "rational drug design" strategies for developing antivirals have tried to attack viruses at every stage of their life cycles. Some species of mushrooms have been found to contain multiple antiviral chemicals with similar synergistic effects.[6] Compounds isolated from fruiting bodies and filtrates of various mushrooms have broad-spectrum antiviral activities, but successful production and availability of such compounds as frontline antiviral is a long way away.[7] Viral life cycles vary in their precise details depending on the type of virus, but they all share a general pattern:

  1. Attachment to a host cell.
  2. Release of viral genes and possibly enzymes into the host cell.
  3. Replication of viral components using host-cell machinery.
  4. Assembly of viral components into complete viral particles.
  5. Release of viral particles to infect new host cells.

Before cell entry[edit]


This stage of viral replication can be inhibited in two ways:



Entry inhibitor[edit]




Uncoating inhibitor[edit]




Some scientists are making the case that a vaccine against rhinoviruses, the predominant cause of the common cold, is achievable. Vaccines that combine dozens of varieties of rhinovirus at once are effective in stimulating antiviral antibodies in mice and monkeys, researchers have reported in Nature Communications in 2016.

Rhinoviruses are the most common cause of the common cold; other viruses such as respiratory syncytial virus, parainfluenza virus and adenoviruses can cause them too. Rhinoviruses also exacerbate asthma attacks. Although rhinoviruses come in many varieties, they do not drift to the same degree that influenza viruses do. A mixture of 50 inactivated rhinovirus types should be able to stimulate neutralizing antibodies against all of them to some degree.

During viral synthesis[edit]


Reverse transcription[edit]




Another target being considered for HIV antivirals include RNase H—which is a component of reverse transcriptase that splits the synthesized DNA from the original viral RNA.







Morpholino oligos have been used to experimentally suppress many viral types:




Protein processing and targeting[edit]


Protease inhibitors[edit]


Protease inhibitors have also been seen in nature. A protease inhibitor was isolated from the Shiitake mushroom (Lentinus edodes).[21] The presence of this may explain the Shiitake mushroom's noted antiviral activity in vitro.[22]

Long dsRNA helix targeting[edit]

Most viruses produce long dsRNA helices during transcription and replication. In contrast, uninfected mammalian cells generally produce dsRNA helices of fewer than 24 base pairs during transcription. DRACO (double-stranded RNA activated caspase oligomerizer) is a group of experimental antiviral drugs initially developed at the Massachusetts Institute of Technology. In cell culture, DRACO was reported to have broad-spectrum efficacy against many infectious viruses, including dengue flavivirus, Amapari and Tacaribe arenavirus, Guama bunyavirus, H1N1 influenza and rhinovirus, and was additionally found effective against influenza in vivo in weanling mice. It was reported to induce rapid apoptosis selectively in virus-infected mammalian cells, while leaving uninfected cells unharmed.[23] DRACO effects cell death via one of the last steps in the apoptosis pathway in which complexes containing intracellular apoptosis signalling molecules simultaneously bind multiple procaspases. The procaspases transactivate via cleavage, activate additional caspases in the cascade, and cleave a variety of cellular proteins, thereby killing the cell.


Rifampicin acts at the assembly phase.[24]

Release phase[edit]


Immune system stimulation[edit]

Rather than attacking viruses directly, a second category of tactics for fighting viruses involves encouraging the body's immune system to attack them. Some antivirals of this sort do not focus on a specific pathogen, instead stimulating the immune system to attack a range of pathogens.

One of the best-known of this class of drugs are interferons, which inhibit viral synthesis in infected cells.[25] One form of human interferon named "interferon alpha" is well-established as part of the standard treatment for hepatitis B and C,[26] and other interferons are also being investigated as treatments for various diseases.


Antiviral drug resistance[edit]

Antiviral resistance can be defined by a decreased susceptibility to a drug caused by changes in viral genotypes. In cases of antiviral resistance, drugs have either diminished or no effectiveness against their target virus.[29] The issue inevitably remains a major obstacle to antiviral therapy as it has developed to almost all specific and effective antimicrobials, including antiviral agents.[30]

The Centers for Disease Control and Prevention (CDC) inclusively recommends anyone six months and older to get a yearly vaccination to protect them from influenza A viruses (H1N1) and (H3N2) and up to two influenza B viruses (depending on the vaccination).[29] Comprehensive protection starts by ensuring vaccinations are current and complete. However, vaccines are preventative and are not generally used once a patient has been infected with a virus. Additionally, the availability of these vaccines can be limited based on financial or locational reasons which can prevent the effectiveness of herd immunity, making effective antivirals a necessity.[29]

The three FDA-approved neuraminidase antiviral flu drugs available in the United States, recommended by the CDC, include: oseltamivir (Tamiflu), zanamivir (Relenza), and peramivir (Rapivab).[29] Influenza antiviral resistance often results from changes occurring in neuraminidase and hemagglutinin proteins on the viral surface. Currently, neuraminidase inhibitors (NAIs) are the most frequently prescribed antivirals because they are effective against both influenza A and B. However, antiviral resistance is known to develop if mutations to the neuraminidase proteins prevent NAI binding.[31] This was seen in the H257Y mutation, which was responsible for oseltamivir resistance to H1N1 strains in 2009.[29] The inability of NA inhibitors to bind to the virus allowed this strain of virus with the resistance mutation to spread due to natural selection. Furthermore, a study published in 2009 in Nature Biotechnology emphasized the urgent need for augmentation of oseltamivir (Tamiflu) stockpiles with additional antiviral drugs including zanamivir (Relenza). This finding was based on a performance evaluation of these drugs supposing the 2009 H1N1 'Swine Flu' neuraminidase (NA) were to acquire the Tamiflu-resistance (His274Tyr) mutation which is currently widespread in seasonal H1N1 strains.[32]

Origin of antiviral resistance[edit]

The genetic makeup of viruses is constantly changing, which can cause a virus to become resistant to currently available treatments.[33] Viruses can become resistant through spontaneous or intermittent mechanisms throughout the course of an antiviral treatment.[29] Immunocompromised patients, more often than immunocompetent patients, hospitalized with pneumonia are at the highest risk of developing oseltamivir resistance during treatment.[29] Subsequent to exposure to someone else with the flu, those who received oseltamivir for "post-exposure prophylaxis" are also at higher risk of resistance.[34]

The mechanisms for antiviral resistance development depend on the type of virus in question. RNA viruses such as hepatitis C and influenza A have high error rates during genome replication because RNA polymerases lack proofreading activity.[35] RNA viruses also have small genome sizes that are typically less than 30 kb, which allow them to sustain a high frequency of mutations.[36] DNA viruses, such as HPV and herpesvirus, hijack host cell replication machinery, which gives them proofreading capabilities during replication. DNA viruses are therefore less error prone, are generally less diverse, and are more slowly evolving than RNA viruses.[35] In both cases, the likelihood of mutations is exacerbated by the speed with which viruses reproduce, which provides more opportunities for mutations to occur in successive replications. Billions of viruses are produced every day during the course of an infection, with each replication giving another chance for mutations that encode for resistance to occur.[37]

Multiple strains of one virus can be present in the body at one time, and some of these strains may contain mutations that cause antiviral resistance.[30] This effect, called the quasispecies model, results in immense variation in any given sample of virus, and gives the opportunity for natural selection to favor viral strains with the highest fitness every time the virus is spread to a new host.[38] Also, recombination, the joining of two different viral variants, and reassortment, the swapping of viral gene segments among viruses in the same cell, play a role in resistance, especially in influenza.[36]

Antiviral resistance has been reported in antivirals for herpes, HIV, hepatitis B and C, and influenza, but antiviral resistance is a possibility for all viruses.[30] Mechanisms of antiviral resistance vary between virus types.

Detection of antiviral resistance[edit]

National and international surveillance is performed by the CDC to determine effectiveness of the current FDA-approved antiviral flu drugs.[29] Public health officials use this information to make current recommendations about the use of flu antiviral medications. WHO further recommends in-depth epidemiological investigations to control potential transmission of the resistant virus and prevent future progression.[39] As novel treatments and detection techniques to antiviral resistance are enhanced so can the establishment of strategies to combat the inevitable emergence of antiviral resistance.[40]

Treatment options for antiviral resistant pathogens[edit]

If a virus is not fully wiped out during a regimen of antivirals, treatment creates a bottleneck in the viral population that selects for resistance, and there is a chance that a resistant strain may repopulate the host.[41] Viral treatment mechanisms must therefore account for the selection of resistant viruses.

The most commonly used method for treating resistant viruses is combination therapy, which uses multiple antivirals in one treatment regimen. This is thought to decrease the likelihood that one mutation could cause antiviral resistance, as the antivirals in the cocktail target different stages of the viral life cycle.[42] This is frequently used in retroviruses like HIV, but a number of studies have demonstrated its effectiveness against influenza A, as well.[43] Viruses can also be screened for resistance to drugs before treatment is started. This minimizes exposure to unnecessary antivirals and ensures that an effective medication is being used. This may improve patient outcomes and could help detect new resistance mutations during routine scanning for known mutants.[41] However, this has not been consistently implemented in treatment facilities at this time.


While most antivirals treat viral infection, vaccines are a preemptive first line of defense against pathogens. Vaccination involves the introduction (i.e. via injection) of a small amount of typically inactivated or attenuated antigenic material to stimulate an individual's immune system. The immune system responds by developing white blood cells to specifically combat the introduced pathogen, resulting in adaptive immunity.[44] Vaccination in a population results in herd immunity and greatly improved population health, with significant reductions in viral infection and disease.[45]

Vaccination policy[edit]

Vaccination policy in the United States consists of public and private vaccination requirements. For instance, public schools require students to receive vaccinations (termed "vaccination schedule") for viruses and bacteria such as diphtheria, pertussis, and tetanus (DTaP), measles, mumps, rubella (MMR), varicella (chickenpox), hepatitis B, rotavirus, polio, and more. Private institutions might require annual influenza vaccination. The Center for Disease Control and Prevention has estimated that routine immunization of newborns prevents about 42,000 deaths and 20 million cases of disease each year, saving about $13.6 billion.[46]

Vaccination controversy[edit]

Despite their successes, in the United States there exists plenty of stigma surrounding vaccines that cause people to be incompletely vaccinated. These "gaps" in vaccination result in unnecessary infection, death, and costs.[47] There are two major reasons for incomplete vaccination:

  1. Vaccines, like other medical treatments, have a risk of causing complications in some individuals (allergic reactions). Vaccines do not cause autism, as stated by national health agencies, such as the US Centers for Disease Control and Prevention,[48] the US Institute of Medicine,[49] and the UK National Health Service[50]
  2. Low rates of vaccine-preventable disease, as a result of herd immunity, also make vaccines seem unnecessary and leave many unvaccinated.[51][52]

Although the American Academy of Pediatrics endorses universal immunization,[53] they note that physicians should respect parents' refusal to vaccinate their children after sufficient advising and provided the child does not face a significant risk of infection. Parents can also cite religious reasons to avoid public school vaccination mandates, but this reduces herd immunity and increases risk of viral infection.[45]

Limitations of vaccines[edit]

Vaccines boosts the body's immune system to better attack viruses in the "complete particle" stage, outside of the organism's cells. They traditionally consist of an attenuated (a live weakened) or inactivated (killed) version of the virus. These vaccines can, in very rare cases, harm the host by inadvertently infecting the host with a full-blown viral occupancy[citation needed]. Recently "subunit" vaccines have been devised that consist strictly of protein targets from the pathogen. They stimulate the immune system without doing serious harm to the host[citation needed]. In either case, when the real pathogen attacks the subject, the immune system responds to it quickly and blocks it.

Vaccines are very effective on stable viruses but are of limited use in treating a patient who has already been infected. They are also difficult to successfully deploy against rapidly mutating viruses, such as influenza (the vaccine for which is updated every year) and HIV. Antiviral drugs are particularly useful in these cases.

Antiretroviral therapy as HIV prevention[edit]

Following the HPTN 052 study and PARTNER study, there is significant evidence to demonstrate that antiretroviral drugs inhibit transmission when the HIV virus in the person living with HIV has been undetectable for 6 months or longer.[54][55]

Public policy[edit]

Use and distribution[edit]

Guidelines regarding viral diagnoses and treatments change frequently and limit quality care.[56] Even when physicians diagnose older patients with influenza, use of antiviral treatment can be low.[57] Provider knowledge of antiviral therapies can improve patient care, especially in geriatric medicine. Furthermore, in local health departments (LHDs) with access to antivirals, guidelines may be unclear, causing delays in treatment.[58] With time-sensitive therapies, delays could lead to lack of treatment. Overall, national guidelines, regarding infection control and management, standardize care and improve healthcare worker and patient safety. Guidelines, such as those provided by the Centers for Disease Control and Prevention (CDC) during the 2009 flu pandemic caused by the H1N1 virus, recommend, among other things, antiviral treatment regimens, clinical assessment algorithms for coordination of care, and antiviral chemoprophylaxis guidelines for exposed persons.[59] Roles of pharmacists and pharmacies have also expanded to meet the needs of public during public health emergencies.[60]


Public Health Emergency Preparedness initiatives are managed by the CDC via the Office of Public Health Preparedness and Response.[61] Funds aim to support communities in preparing for public health emergencies, including pandemic influenza. Also managed by the CDC, the Strategic National Stockpile (SNS) consists of bulk quantities of medicines and supplies for use during such emergencies.[62] Antiviral stockpiles prepare for shortages of antiviral medications in cases of public health emergencies. During the H1N1 pandemic in 2009–2010, guidelines for SNS use by local health departments was unclear, revealing gaps in antiviral planning.[58] For example, local health departments that received antivirals from the SNS did not have transparent guidance on the use of the treatments. The gap made it difficult to create plans and policies for their use and future availabilities, causing delays in treatment.

See also[edit]


  2. ^ Rossignol JF (2014). "Nitazoxanide: a first-in-class broad-spectrum antiviral agent". Antiviral Res. 110: 94–103. doi:10.1016/j.antiviral.2014.07.014. PMC 7113776. PMID 25108173. Originally developed and commercialized as an antiprotozoal agent, nitazoxanide was later identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. ... From a chemical perspective, nitazoxanide is the scaffold for a new class of drugs called thiazolides. These small-molecule drugs target host-regulated processes involved in viral replication. ... A new dosage formulation of nitazoxanide is presently undergoing global Phase 3 clinical development for the treatment of influenza. Nitazoxanide inhibits a broad range of influenza A and B viruses including influenza A(pH1N1) and the avian A(H7N9) as well as viruses that are resistant to neuraminidase inhibitors. ... Nitazoxanide also inhibits the replication of a broad range of other RNA and DNA viruses including respiratory syncytial virus, parainfluenza, , rotavirus, norovirus, hepatitis B, hepatitis C, dengue, yellow fever, Japanese encephalitis virus and human immunodeficiency virus in cell culture assays. Clinical trials have indicated a potential role for thiazolides in treating rotavirus and norovirus gastroenteritis and chronic hepatitis B and chronic hepatitis C. Ongoing and future clinical development is focused on viral respiratory infections, viral gastroenteritis and emerging infections such as dengue fever.
  3. ^ Rick Daniels; Leslie H. Nicoll. "Pharmacology – Nursing Management". Contemporary Medical-Surgical Nursing. Cengage Learning, 2011. p. 397.
  4. ^ Kisung Ko, Yoram Tekoah, Pauline M. Rudd, David J. Harvey, Raymond A. Dwek, Sergei Spitsin, Cathleen A. Hanlon, Charles Rupprecht, Bernhard Dietzschold, Maxim Golovkin, and Hilary Koprowski (2003). "Function and glycosylation of plant-derived antiviral monoclonal antibody". PNAS. 100 (13): 8013–18. Bibcode:2003PNAS..100.8013K. doi:10.1073/pnas.0832472100. PMC 164704. PMID 12799460.CS1 maint: uses authors parameter (link)
  5. ^ Schnitzler, P; Schön, K; Reichling, J (2001). "Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture". Die Pharmazie. 56 (4): 343–47. PMID 11338678.
  6. ^ Lindequist, Ulrike; Niedermeyer, Timo H. J.; Jülich, Wolf-Dieter (2005). "The Pharmacological Potential of Mushrooms". Evidence-Based Complementary and Alternative Medicine. 2 (3): 285–99. doi:10.1093/ecam/neh107. PMC 1193547. PMID 16136207.
  7. ^ Pradeep, Prabin; Manju, Vidya; Ahsan, Mohammad Feraz (2019), Agrawal, Dinesh Chandra; Dhanasekaran, Muralikrishnan (eds.), "Antiviral Potency of Mushroom Constituents", Medicinal Mushrooms: Recent Progress in Research and Development, Springer Singapore, pp. 275–97, doi:10.1007/978-981-13-6382-5_10, ISBN 9789811363825
  8. ^ Bishop NE (1998). "Examination of potential inhibitors of hepatitis A virus uncoating". Intervirology. 41 (6): 261–71. doi:10.1159/000024948. PMID 10325536. S2CID 21222121.
  9. ^ Almela MJ, González ME, Carrasco L (May 1991). "Inhibitors of poliovirus uncoating efficiently block the early membrane permeabilization induced by virus particles". J. Virol. 65 (5): 2572–77. doi:10.1128/JVI.65.5.2572-2577.1991. PMC 240614. PMID 1850030.
  10. ^ Beringer, Paul; Troy, David A.; Remington, Joseph P. (2006). Remington, the science and practice of pharmacy. Hagerstwon, MD: Lippincott Williams & Wilkins. p. 1419. ISBN 978-0-7817-4673-1.
  14. ^ McCaffrey AP, Meuse L, Karimi M, Contag CH, Kay MA (2003). "A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice". Hepatology. 38 (2): 503–08. doi:10.1053/jhep.2003.50330. PMID 12883495. S2CID 1612244.
  15. ^ Neuman, B. W.; Stein, D. A.; Kroeker, A. D.; Paulino, A. D.; Moulton, H. M.; Iversen, P. L.; Buchmeier, M. J. (June 2004). "Antisense Morpholino-Oligomers Directed against the 5' End of the Genome Inhibit Coronavirus Proliferation and Growth†". J. Virol. 78 (11): 5891–99. doi:10.1128/JVI.78.11.5891-5899.2004. PMC 415795. PMID 15140987.
  17. ^ Bai J, Rossi J, Akkina R (March 2001). "Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy". AIDS Res. Hum. Retroviruses. 17 (5): 385–99. doi:10.1089/088922201750102427. PMID 11282007.
  18. ^ Alarcón B, González ME, Carrasco L (1988). "Megalomycin C, a macrolide antibiotic that blocks protein glycosylation and shows antiviral activity". FEBS Lett. 231 (1): 207–11. doi:10.1016/0014-5793(88)80732-4. PMID 2834223. S2CID 43114821.
  19. ^ Anderson J, Schiffer C, Lee SK, Swanstrom R (2009). "Viral protease inhibitors". Antiviral Strategies. Handb Exp Pharmacol. Handbook of Experimental Pharmacology. 189. pp. 85–110. doi:10.1007/978-3-540-79086-0_4. ISBN 978-3-540-79085-3. PMC 7120715. PMID 19048198.
  21. ^ Odani S, Tominaga K, Kondou S (1999). "The inhibitory properties and primary structure of a novel serine proteinase inhibitor from the fruiting body of the basidiomycete, Lentinus edodes". European Journal of Biochemistry. 262 (3): 915–23. doi:10.1046/j.1432-1327.1999.00463.x. PMID 10411656.
  23. ^ Rider TH, Zook CE, Boettcher TL, Wick ST, Pancoast JS, Zusman BD (2011). "Broad-spectrum antiviral therapeutics". PLOS ONE. 6 (7): e22572. Bibcode:2011PLoSO...622572R. doi:10.1371/journal.pone.0022572. PMC 3144912. PMID 21818340.CS1 maint: multiple names: authors list (link)
  24. ^ Sodeik B, Griffiths G, Ericsson M, Moss B, Doms RW (1994). "Assembly of vaccinia virus: effects of rifampin on the intracellular distribution of viral protein p65". J. Virol. 68 (2): 1103–14. doi:10.1128/JVI.68.2.1103-1114.1994. PMC 236549. PMID 8289340.
  28. ^ Akay S, Karasu Z (November 2008). "Hepatitis B immune globulin and HBV-related liver transplantation". Expert Opin Biol Ther (Submitted manuscript). 8 (11): 1815–22. doi:10.1517/14712598.8.11.1815. PMID 18847315. S2CID 71595650.
  29. ^ a b c d e f g h "Influenza Antiviral Drug Resistance| Seasonal Influenza (Flu) | CDC". 25 October 2018.
  30. ^ a b c Pillay, D; Zambon, M (1998). "Antiviral Drug Resistance". BMJ. 317 (7159): 660–62. doi:10.1136/bmj.317.7159.660. PMC 1113839. PMID 9728000.
  31. ^ Moss, Ronald; Davey, Richard; Steigbigel, Roy; Fang, Fang (June 2010). "Targeting pandemic influenza: a primer on influenza antivirals and drug resistance". Journal of Antimicrobial Chemotherapy. 65 (6): 1086–93. doi:10.1093/jac/dkq100. PMID 20375034. Retrieved 30 October 2018.
  32. ^ Soundararajan, V; Tharakaraman, K; Raman, R; Raguram, S; Shriver, Z; Sasisekharan, V; Sasisekharan, R (June 2009). "Extrapolating from sequence--the 2009 H1N1 'swine' influenza virus". Nature Biotechnology. 27 (6): 510–13. doi:10.1038/nbt0609-510. PMID 19513050. S2CID 22710439.
  33. ^ Nijhuis, M; van Maarseveen, NM; Boucher, CA (2009). Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handbook of Experimental Pharmacology. 189. pp. 299–320. doi:10.1007/978-3-540-79086-0_11. ISBN 978-3-540-79085-3. PMID 19048205.
  34. ^ "WHO | Antiviral use and the risk of drug resistance".
  35. ^ a b Lodish, H; Berk, A; Zipursky, S (2000). Molecular Cell Biology: Viruses – Structure, Function, and Uses. New York, New York: W. H. Freeman and Company. Retrieved 1 December 2018.
  36. ^ a b Racaniello, Vincent. "The error-prone ways of RNA synthesis". Virology Blog. Retrieved 1 December 2018.
  37. ^ Thebaud, G; Chadeouf, J; Morelli, M; McCauley, J; Haydon, D (2010). "The relationship between mutation frequency and replication strategy in positive sense single-stranded RNA viruses". Proc. Biol. Sci. 277 (1682): 809–17. doi:10.1098/rspb.2009.1247. PMC 2842737. PMID 19906671.
  38. ^ "Viruses are models for embracing diversity". Nature Microbiology. 3 (4): 389. 2018. doi:10.1038/s41564-018-0145-3. PMID 29588540.
  39. ^ Hayden, FG; de Jong, MD (1 January 2011). "Emerging influenza antiviral resistance threats". The Journal of Infectious Diseases. 203 (1): 6–10. doi:10.1093/infdis/jiq012. PMC 3086431. PMID 21148489.
  40. ^ Kimberlin, DW; Whitley, RJ (March 1996). "Antiviral resistance: mechanisms, clinical significance, and future implications". The Journal of Antimicrobial Chemotherapy. 37 (3): 403–21. doi:10.1093/jac/37.3.403. PMID 9182098.
  41. ^ a b Irwin, K; Renzette, N; Kowalik, T; Jensen, J (2016). "Antiviral drug resistance as an adaptive process". Virus Evolution. 2 (1): vew014. doi:10.1093/ve/vew014. PMC 5499642. PMID 28694997.
  42. ^ Moscona, A (2009). "Global transmission of oseltamivir-resistant influenza". New England Journal of Medicine. 360 (10): 953–56. doi:10.1056/NEJMp0900648. PMID 19258250. S2CID 205104988.
  43. ^ Strasfeld, L; Chou, S (2010). "Antiviral Drug Resistance: Mechanisms and Clinical Implications". Infectious Disease Clinics of North America. 24 (2): 413–37. doi:10.1016/j.idc.2010.01.001. PMC 2871161. PMID 20466277.
  44. ^ "Understanding How Vaccines Work" (PDF). Center for Disease Control. Retrieved 20 October 2016.
  45. ^ a b Heymann, D. L.; Aylward, R. B. (2006). Mass vaccination: When and why. Current Topics in Microbiology and Immunology. 304. pp. 1–16. doi:10.1007/3-540-36583-4_1. ISBN 978-3-540-29382-8. PMID 16989261.
  46. ^ Seither, R.; Masalovich, S.; Knighton, C. L.; Mellerson, J.; Singleton, J. A.; Greby, S. M.; Centers for Disease Control Prevention (CDC) (2014). "Vaccination Coverage Among Children in Kindergarten—United States, 2013–14 School Year". MMWR. 63 (41): 913–920. PMC 4584748. PMID 25321068.
  47. ^ Omer, SB; Salmon, DA; Orenstein, WA; deHart, MP; Halsey, N (May 2009). "Vaccine Refusal, Mandatory Immunization, and the Risks of Vaccine-Preventable Diseases". New England Journal of Medicine. 360 (19): 1981–88. doi:10.1056/NEJMsa0806477. PMID 19420367.
  48. ^ "Vaccines Do Not Cause Autism". Centers for Disease Control and Prevention. 23 November 2015. Retrieved 20 October 2016.
  50. ^ "MMR vaccine". National Health Service. Retrieved 20 October 2016.
  51. ^ Hendriksz T, Malouf PH, Sarmiento S, Foy JE. "Overcoming patient barriers to immunizations". AOA Health Watch. 2013: 9–14.CS1 maint: multiple names: authors list (link)
  52. ^ "Barriers and Strategies to Improving Influenza Vaccination among Health Care Personnel". Centers for Disease Control and Prevention. 7 September 2016. Retrieved 17 September 2016.
  53. ^ Diekema DS (2005). "Responding to parental refusals of immunization of children". Pediatrics. 115 (5): 1428–31. doi:10.1542/peds.2005-0316. PMID 15867060.
  54. ^ "HPTN 052". HPTN. Retrieved 29 September 2017.
  55. ^ Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutiérrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kümmerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J (12 July 2016). "Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy". JAMA. 316 (2): 171–181. doi:10.1001/jama.2016.5148. PMID 27404185.
  56. ^ Kunin, Marina; Engelhard, Dan; Thomas, Shane; Ashworth, Mark; Piterman, Leon (15 October 2015). "Challenges of the Pandemic Response in Primary Care during Pre-Vaccination Period: A Qualitative Study". Israel Journal of Health Policy Research. 4 (1): 32. doi:10.1186/s13584-015-0028-5. PMC 4606524. PMID 26473026.
  57. ^ Lindegren, Mary Louise; Griffin, Marie R.; Williams, John V.; Edwards, Kathryn M.; Zhu, Yuwei; Mitchel, Ed; Fry, Alicia M.; Schaffner, William; Talbot, H. Keipp; Pyrc, Krzysztof (25 March 2015). "Antiviral Treatment among Older Adults Hospitalized with Influenza, 2006–2012". PLOS ONE. 10 (3): e0121952. Bibcode:2015PLoSO..1021952L. doi:10.1371/journal.pone.0121952. PMC 4373943. PMID 25807314.
  58. ^ a b NACCHO (December 2010). Public Health Use and Distribution of Antivirals: NACCHO Think Tank Meeting Report (PDF) (Report). Archived from the original (PDF) on 22 October 2016. Retrieved 21 October 2016.
  59. ^ Centers for Disease Control and Prevention. "H1N1 Flu".
  60. ^ Hodge, J G; Orenstein, D G. "Antiviral Distribution and Dispensing A Review of Legal and Policy Issues". Association of State and Territorial Health Officials (ASTHO).
  61. ^ "Funding and Guidance for State and Local Health Departments". Centers for Disease Control and Prevention. Retrieved 21 October 2016.
  62. ^ "Strategic National Stockpile (SNS)". Centers for Disease Control and Prevention. Retrieved 21 October 2016.
  63. ^ Freije Catherine A., Myhrvold Cameron, Boehm Chloe K., Lin Aaron E., Welch Nicole L., Carter Amber, Metsky Hayden C., Luo Cynthia Y., Abudayyeh Omar O., Gootenberg Jonathan S., Yozwiak Nathan L., Zhang Feng, Sabeti Pardis C. (2019). "Programmable Inhibition and Detection of RNA Viruses Using Cas13". Molecular Cell. 76 (5): 826–837.e11. doi:10.1016/j.molcel.2019.09.013. PMC 7422627. PMID 31607545.CS1 maint: multiple names: authors list (link)